HCG now has 40+ Oncologist Experts recruited in this quarter with a strength of 450 Overall Doctors.
HCG Introduced First Microsoft Holo Lens which is nothing but the Next Generation Holographic Headset for the Virtual Reality System.
Provides Healthcare Training & Medical Education Of Metaverse with 200 Virtual Content.
Ranked No1 Cancer centers in 12+ Cities.
HCG Discontinued Kochi Plan & take the investment back of 2.5 Cr.
Consolidated Revenue of 364.6Cr, EBITDA of Rs.66.1Cr as compared to 43.1Cr in the corresponding quarter in the previous year (Q4FY21).
Operational EBITDA for Existing Center is 61 Cr. with 17.3% EBITDA Margin.
Operating EBITDA for New Centers is 2.1Cr as compared to a loss of 4.8Cr in Q4FY21.
Proforma PAT is 6.7Cr including the Project cost fee of 2.5cr from the Discontinuation of Kochi Center.
The region-wise Contribution, Karnataka Region Contributed 36% of revenue, Gujrat Contributed 26% of Revenue & Maharashtra Contributed 17% of Revenue.
Revenue From New Centers is 82.6Cr compared to 53.5Cr in Q4FY21. With 54.3% Growth
Center Of Excellence Revenue Growth is 39.6% with 59,800rs/Day ARPOB.
In Gujrat-Oncology Center Revenue Growth is 43%, and Multispeciality Growth is 38%.
In Maharashtra, Nagpur & Borivali Center Grew by 79% YOY. , East India Grew By 34%YOY.
CAPEX of HCG Centers, For Existing Center 45.8Cr & 24.6Cr for new Centers.
Net Debt of Rs.697.2Cr
Q4FY22,ARPOB is 36,697rs/Day & AOR is 60%
Overall ARPOB for FY22 is 38,805rs/Day.
Project Updates:-
Started Investment in Robots Digital Platform.
HCG started recruiting the Senior team for better Oncology Treatment.
HCG Discontinued Kochi Plan & take the investment back of 2.5 Cr.
HCG will be starting the phase II In Ahmedabad with Dedicated Oncology Center
Q&A Highlights
HCG is not looking for any New Centers, and try to focus on its consolidation.
March has ended with the Highest International Patient growth of 4% on the top line despite Covid-19 Inflation.
HCG will be starting phase II In Ahmedabad with Dedicated Oncology Center.
HCG Also focuses on Banglore Center, as the Replacement for Equipment & All other stuff in which their more CAPEX investment as a Replacement CAPEX.
Center of Excellence, ROCE is 25% – 26%, Ahmedabad ROCE is more than the COE as it is a Multispecialty Hospital.
Because of Low Cost & Higher Asset Turnover, The EBITDA Margin is 20% for an existing center in Tier2 and Tier3 cities.
50+ Oncologists in Tier2, Tier 3 Cities.
Nashik Center is in Partnership with Raj Nagarkar who is also an oncologist in the Nashik region. HCG gets the 51% Stake & Raj Nagarkar gets the 49% Stake in this partnership Model.
Nashik Center has 220Beds & 3Linear Accelerator.
Raj Nagarkar is also a Partner with Kims Hospital which is a Multispecialty Hospital.
Multiple DIgital Initiative has been taken in this quarter.